EE200300025A - CRF2 ligandid kasutamiseks kombineeritud ravis - Google Patents

CRF2 ligandid kasutamiseks kombineeritud ravis

Info

Publication number
EE200300025A
EE200300025A EEP200300025A EEP200300025A EE200300025A EE 200300025 A EE200300025 A EE 200300025A EE P200300025 A EEP200300025 A EE P200300025A EE P200300025 A EEP200300025 A EE P200300025A EE 200300025 A EE200300025 A EE 200300025A
Authority
EE
Estonia
Prior art keywords
crf2
ligands
combination therapy
therapy
combination
Prior art date
Application number
EEP200300025A
Other languages
English (en)
Estonian (et)
Inventor
Peng Ho Siew
Original Assignee
Bristol-Myers Squibb Pharma Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company
Publication of EE200300025A publication Critical patent/EE200300025A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300025A 2000-07-19 2001-07-19 CRF2 ligandid kasutamiseks kombineeritud ravis EE200300025A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21939100P 2000-07-19 2000-07-19
PCT/US2001/022808 WO2002005749A2 (en) 2000-07-19 2001-07-19 Crf2 ligands in combination therapy

Publications (1)

Publication Number Publication Date
EE200300025A true EE200300025A (et) 2005-04-15

Family

ID=22819077

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300025A EE200300025A (et) 2000-07-19 2001-07-19 CRF2 ligandid kasutamiseks kombineeritud ravis

Country Status (20)

Country Link
US (2) US20020035083A1 (cs)
EP (1) EP1383460A2 (cs)
JP (1) JP2004513880A (cs)
KR (1) KR20040014926A (cs)
CN (1) CN1501976A (cs)
AU (1) AU2001280632A1 (cs)
BG (1) BG107364A (cs)
BR (1) BR0111937A (cs)
CA (1) CA2416986A1 (cs)
CZ (1) CZ2003159A3 (cs)
EE (1) EE200300025A (cs)
HU (1) HUP0301833A3 (cs)
IL (1) IL153264A0 (cs)
IS (1) IS6673A (cs)
MX (1) MXPA02012721A (cs)
NO (1) NO20030214D0 (cs)
PL (1) PL365955A1 (cs)
RU (1) RU2003104509A (cs)
WO (1) WO2002005749A2 (cs)
ZA (1) ZA200300088B (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073149A1 (en) * 2005-12-22 2007-06-28 Keygene N.V. Alternative nucleotides for improved targeted nucleotide exchange
WO2007100775A2 (en) * 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2692039C (en) * 2007-06-13 2019-07-02 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
CN104231059B (zh) * 2013-06-19 2016-12-28 深圳翰宇药业股份有限公司 一种多肽及其制备方法和用途
KR20190084055A (ko) 2016-10-20 2019-07-15 코르텐 인코포레이티드 부적응 스트레스 반응에서 기인한 질환의 치료 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) * 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
CA2193072A1 (en) * 1994-06-14 1995-12-21 Derek Chalmers Corticotropin-releasing factor2 receptors
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5663292A (en) * 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US6214797B1 (en) * 1995-06-13 2001-04-10 The Salk Institute For Biological Studies Urocortin peptides, nucleic acid encoding same methods for using same
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US5861398A (en) * 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
GB9717087D0 (en) * 1997-08-12 1997-10-15 Ciba Geigy Ag Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
JP2004513880A (ja) 2004-05-13
CN1501976A (zh) 2004-06-02
KR20040014926A (ko) 2004-02-18
IS6673A (is) 2003-01-08
ZA200300088B (en) 2005-05-09
RU2003104509A (ru) 2004-08-27
EP1383460A2 (en) 2004-01-28
WO2002005749A2 (en) 2002-01-24
IL153264A0 (en) 2003-07-06
US20050059627A1 (en) 2005-03-17
NO20030214L (no) 2003-01-16
CA2416986A1 (en) 2002-01-24
PL365955A1 (en) 2005-01-24
BG107364A (bg) 2003-07-31
HUP0301833A3 (en) 2005-12-28
NO20030214D0 (no) 2003-01-16
BR0111937A (pt) 2005-04-12
AU2001280632A1 (en) 2002-01-30
CZ2003159A3 (cs) 2004-02-18
MXPA02012721A (es) 2003-04-25
WO2002005749A3 (en) 2003-11-06
HUP0301833A2 (hu) 2003-09-29
US20020035083A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
EE04528B1 (et) Teraapias kasutatavad spirofuropridiinide aralklamiinid
AR028622A1 (es) Derivados de tropano utiles en terapia
EP1296697A4 (en) Therapeutic agents - i
GB0016787D0 (en) Compounds useful in therapy
NO20013745D0 (no) Ventiler for bruk i brönner
DE60125859D1 (de) Poliervorrichtung
DE50105593D1 (de) Schleifvorrichtung
ATE327232T1 (de) Heterozyklylalkylindole oder -azaindole als 5- hydroxytryptamine-6 liganden
NO20024663D0 (no) Difenyleterforbindelser nyttige i terapi
NO20030095L (no) Slipeapparat
NO20020903D0 (no) Örepluggdispenser
DE60122236D1 (de) Poliervorrichtung
DE50105754D1 (de) Schleifvorrichtung
DE60137515D1 (de) Ndbreite in gesampelten systemen
PT1036525E (pt) Melhorias em suportes para pipas
DE60034659D1 (de) Filtervorrichtung mit sandfilterbett
EP1478378A4 (en) ANTIALLERGIC COMPLEX MOLECULES
DE50104735D1 (de) Schleifvorrichtung
NO20030214L (no) CRF2 ligander i kombinasjonsterapi
GB0022922D0 (en) Compounds for use in medicine
GB0014046D0 (en) Compounds useful in therapy
ES1045346Y (es) Maquina lijadora perfeccionada
GB0014866D0 (en) Compounds useful in therapy
GB0015835D0 (en) Compounds useful in therapy
IDP000027294A (id) Kayu lapis